Идиопатическая интерстициальная пневмония у взрослых и детей (обзор литературы)

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 2002; 165 (2): 277–304.

2. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. 2000; 161(2, pt 1): 646–664.

3. Авдеева О. Е., Авдеев С. Н. Идиопатический фиброзирующий альвеолит: современные подходы к диагностике и терапии. Consilium Medicum 2002; 4 (4): 195–201.

4. Чучалин А. Г. Идиопатический легочный фиброз. Тер. арх. 2000; 72 (3): 5–12.

5. Hagood J. S., Vaughan D. J., Zimmerman J. et al. Interstitial lung disease in children. Article in E medicine. Last Updated: August 5, 2002. Доступен по URL: http://www.emedicine.com/ped/topic1950.htm.

6. Dinwiddie R., Sharief N., Crawford O. Idiopathic interstitial pneumonitis in children: a national survey in the United Kingdom and Ireland. Pediatr. Pulmonol. 2002; 34 (1): 23–29.

7. Fan L.L., Kozinetz C.A., Deterding R.R. et al. Evaluation of a diagnostic approach to pediatric interstitial lung disease. Pediatrics 1998; 101(1, pt 1): 82–85.

8. Илькович М. М., Новикова Л. Н. Идиопатический фиброзирующий альвеолит: противоречия в современных представлениях. Пульмонология 2003; 1: 98–101.

9. Coultas D.B., Zumwalt R.E., Black W.C. et al. The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 1994; 150 (4): 967–972.

10. Von Plessen C., Grinde O., Gulsvik A. Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respir. Med. 2003; 97 (4): 428–435.

11. Hodgson U., Laitinen T., Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 2002; 57 (4): 338–342.

12. Hubbard R., Johnston I., Coultas D. B. et al. Mortality rates from cryptogenic fibrosing alveolitis in seven countries. Thorax 1996; 51 (7): 711–716.

13. Nicholson A.G., Colby T.V., Du Bois R. M. et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am. J. Respir. Crit. Care Med. 2000; 162 (6): 2213–2217.

14. Quefatieh A., Stone C. H., Digiovine B. et al. Low hospital mortality in patients with acute interstitial pneumonia. Chest 2003; 124 (2): 554–559.

15. Barbato A., Panizzolo C., Cracco A. et al. Interstitial lung disease in children: a multicentre survey on diagnostic approach. Eur. Respir. J. 2000; 16 (3): 509–513.

16. Fan L.L., Mullen A.L., Brugman S. M. et al. Clinical spectrum of chronic interstitial lung disease in children. J. Pediatr. 1992; 121 (6): 867–872.

17. Nicholson A.G., Kim H., Corrin B. et al. The value of classifying interstitial pneumonitis in childhood according to defined histological patterns. Histopathology 1998; 33 (3): 203–211.

18. Katzenstein A.L., Myers J.L. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. J. Respir. Crit. Care Med. 1998; 157 (4, pt 1): 1301–1315.

19. Barbato A., Panizzolo C. Recent advances. Chronic interstitial lung disease in children. Paediatr. Respir. Rev. 2000; 1 (2): 172–178.

20. Fan L.L., Kozinetz C.A. Factors influencing survival in children with chronic interstitial lung disease. Am. J. Respir. Crit. Care Med. 1997; 156 (3, pt 1): 939–942.

21. Desai S. R., Ryan S. M., Colby T. V. Smoking related interstitial lung diseases: histopathological and imaging perspectives. Clin. Radiol. 2003; 58 (4): 259–268.

22. Fan L.L., Langston C. Pediatric interstitial lung disease: children are not small adults. Am. J. Respir. Crit. Care Med. 2002; 165 (11): 1466–1467.

23. Langston C., Fan L.L. Diffuse interstitial lung disease in infants. Pediatr. Pulmonol. 2001; suppl. 23: 74–76.

24. Canakis A. M., Cutz E., Manson D. et al. Pulmonary interstitial glycogenosis: a new variant of neonatal interstitial lung disease. Am. J. Respir. Crit. Care Med. 2002; 165 (11): 1557–1565.

25. Hodgman J.E. Relationship between Wilson Mikity syndrome and the new bronchopulmonary dysplasia. Pediatrics 2003; 112 (6, pt 1): 1414–1415.

26. Takami T., Kumada A., Takei Y. et al. A case of Wilson-Mikity syndrome with high serum KL 6 levels. J. Perinatol. 2003; 23(1): 56–58.

27. Schroeder S.A., Shannon D.C., Mark E.J. Cellular interstitial pneumonitis in infants. A clinicopathologic study. Chest 1992; 101 (4): 1065–1069.

28. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 40 1999. A four month-old girl with chronic cyanosis and diffuse pulmonary infiltrates. N. Engl. J. Med. 1999; 341 (27): 2075–2083.

29. Hull J., Chow C.W., Robertson C.F. Chronic idiopathic bronchiolitis of infancy. Arch. Dis. Child. 1997; 77 (6): 512–515.

30. Deterding R.R., Fan L.L., Morton R. et al. Persistent tachypnea of infancy (PTI) — a new entity. Pediatr. Pulmonol. 2001; suppl. 23: 72–73.

31. Aquino S.L., Schechter M.S., Chiles C. et al. High resolution inspiratory and expiratory CT in older children and adults with bronchopulmonary dysplasia. Am. J. Roentgenol. 1999; 173 (4): 963–967.

32. Swaye P., Van Ordstrand H.S., Mccormack L.J. et al. Familial Hamman Rich syndrome. Report of eight cases. Dis. Chest 1969; 55 (1): 7–12.

33. Zanutto A., Chabot F., Martinet Y. et al. Familial diffuse interstitial fibrosis of prolonged onset worsening during pregnancy. Rev. Mal. Respir. 2003; 20 (4): 628–632.

34. Marshall R.P., Puddicombe A., Cookson W.O. et al. Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax 2000; 55 (2): 143–146.

35. Amin R. S., Wert S. E., Baughman R. P. et al. Surfactant protein deficiency in familial interstitial lung disease. J. Pediatr. 2001; 139 (1): 85–92.

36. Nogee L. M., Dunbar A. E. 3&rd, Wert S. et al. Mutations in the surfactant protein C gene associated with interstitial lung disease. Chest 2002; 121 (3, suppl.): 20–21.

37. Hamvas A., Nogee L.M., White F.V. et al. Progressive lung disease and surfactant dysfunction with a deletion of surfactant protein C gene. Am. J. Respir. Cell Mol. Biol. 2003; Published ahead of print on December 4, 2003.

38. Lahti M., Marttila R., Hallman M. Surfactant protein C gene variation in the Finnish population — association with perinatal respiratory disease. Eur. J. Hum. Genet. 2004; 12 (4): 312–320.

39. Thomas A.Q., Lane K., Phillips J., 3&rd et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am. J. Respir. Crit. Care Med. 2002; 165 (9): 1322–1328.

40. Yoshioka Y., Saiki S., Tsutsumi&Ishii Y. et al. Adult-onset familial pulmonary fibrosis in Japanese brothers. Pathol. Int. 2004; 54 (1): 41–46.

41. Buchino J.J., Keenan W. J., Algren J.T. et al. Familial desquamative interstitial pneumonitis occurring in infants. Am. J. Med. Genet. 1987; 3 (suppl.): 285–291.

42. Tal A., Maor E., Bar&Ziv J. et al. Fatal desquamative interstitial pneumonia in three infants siblings. J. Pediatr. 1984; 104 (6): 873–876.

43. Du Bois R.M. The genetic predisposition to interstitial lung disease: functional relevance. Chest 2002; 121 (3, suppl.): 14–20.

44. Волков И.К. Альвеолиты. В кн.: Таточенко В.К. (ред.) Практическая пульмонология детского возраста. М.; 2000, 209–214.

45. Шмелев Е.И. Дифференциальная диагностика интерстициальных болезней легких. Consilium Medicum 2003; 4: 176–181.

46. Wittram C., Mark E.J., Mcloud T.C. CT-histologic correlation of the ATS/ERS 2002 classification of idiopathic interstitial pneumonias. Radiographics 2003; 23 (5): 1057–1071.

47. Lynch D. A., Hay T., Newell J. D. Jr. et al. Pediatric diffuse lung disease: diagnosis and classification using high resolution CT. Am. J. Roentgenol. 1999; 173 (3): 713–718.

48. Greene K.E., King T.E., Jr., Kuroki Y. et al. Serum surfactant proteins A and D as biomarkers in idiopathic pulmonary fibrosis. Eur. Respir. J. 2002; 19 (3): 439–446.

49. Ogawa N., Shimoyama K., Kawabata H. et al. Clinical significance of serum KL-6 and SP-D for the diagnosis and treatment of interstitial lung disease in patients with diffuse connective tissue disorders. Ryumachi 2003; 43 (1): 19–28.

50. Kuwano K., Maeyama T., Inoshima I. et al. Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases. Respirology 2002; 7 (1): 15–21.

51. Авдеева О.Е., Лебедин С., Авдеев С.Н. и др. Гликозилированный муцин-антиген 3EG5 — cывороточный маркер активности и тяжести при интерстициальных заболеваниях легких. Пульмонология 1998; 2: 22–27.

52. Veeraraghavan S., Latsi P. I., Wells A. U. et al. BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. Eur. Respir. J. 2003; 22 (2): 239–244.

53. Carpagnano G.E., Kharitonov S.A., Wells A.U. et al. Increased vitronectin and endothelin-1 in the breath condensate of patients with fibrosing lung disease. Respiration 2003; 70 (2): 154–160.

54. Kharitonov S.A., Barnes P.J. Biomarkers of some pulmonary diseases in exhaled breath. Biomarkers 2002; 7 (1): 1–32.

55. Utz J.P., Ryu J.H., Douglas W.W. et al. High short-term mortality following lung biopsy for usual interstitial pneumonia. Eur. Respir. J. 2001; 17 (2): 175–179.

56. Paul K., Klettke U., Moldenhauer J. et al. Increasing dose of methylprednisolone pulse therapy treats desquamative interstitial pneumonia in a child. Eur. Respir. J. 1999; 14 (6): 1429–1432.

57. Desmarquest P., Tamalet A., Fauroux B. et al. Chronic interstitial lung disease in children: response to high dose intravenous methylprednisolone pulses. Pediatr. Pulmonol. 1998; 26 (5): 332–338.

58. Green F.H. Overview of pulmonary fibrosis. Chest 2002; 122 (6, suppl): 334–339.

59. Yoshioka Y., Ohwada A., Dambara T. et al. CD4+ T cells in lung tissue predict responsiveness to cyclosporin A in interstitial pneumonia. Respirology 2002; 7 (4): 299–304.

60. Honore I., Nunes H., Groussard O. et al. Acute respiratory failure after interferon-gamma therapy of end-stage pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 167 (7): 953–957.